A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections

  15 September 2022

Drug-resistant Gram-positive bacterial infections remain a critical concern, and new treatment modalities against them are needed in the clinic. Blaskovich et al. optimized a vancomycin-derived antibiotic bearing a membrane-targeting glycopeptide and demonstrated that this compound was effective in multiple mouse models of Gram-positive infections, including difficult-to-treat biofilms. The optimized compound was more potent than its parent, vancomycin, and had a low rate of resistance, suggesting that this candidate compound may warrant further development.

Author(s): MARK A. T. BLASKOVICH et al
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





EADA 2023

Emerging Antimicrobials and Diagnostics in AMR 2023

International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands
16/17 November

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!